Literature DB >> 7199538

Significance of cross-linking of alpha 2-plasmin inhibitor to fibrin in inhibition of fibrinolysis and in hemostasis.

Y Sakata, N Aoki.   

Abstract

When blood is clotted, alpha(2)-plasmin inhibitor (alpha(2)PI) is cross-linked to fibrin by activated fibrin-stabilizing factor (activated coagulation Factor XIII, plasma transglutaminase). The amount of cross-linked alpha(2)-PI is proportional to the amount of alpha(2)PI present at the time of clotting. Plasma from a patient with congenital deficiency of alpha(2)PI was supplemented with various amounts of purified alpha(2)PI. Clots were prepared from these plasmas and were suspended in plasma containing a normal concentration of alpha(2)PI, and spontaneous clot lysis was observed. When the clot was formed in the presence of calcium ions and thereby allowing cross-linking to occur, the rate and extent of fibrinolysis were found to be inversely proportional to the concentrations of alpha(2)PI present in the clot at the time of clotting. When the clot was formed in the absence of calcium ions so that no cross-linking occurred, the clot underwent fibrinolysis at similar rates, regardless of the concentrations of alpha(2)PI in the clot. When the clot formed in the presence of calcium ions was squeezed and washed to remove unbound proteins before being suspended in plasma, the extent of fibrinolysis was also inversely proportional to the amount of alpha(2)PI cross-linked to fibrin. Similar results were obtained when the clot was suspended in buffered saline instead of plasma. These observations suggest that spontaneous fibrinolysis is mainly carried out by plasminogen/plasminogen activator bound to fibrin, and this fibrinolysis caused by fibrin-associated activation of plasminogen was mainly inhibited by alpha(2)PI cross-linked to fibrin. To further support this concept, alpha(2)PI treated with activated fibrin-stabilizing factor and that had lost most of its cross-linking capacity was used in similar experiments. This modified alpha(2)PI had the same inhibitory activity on plasmin as the native inhibitor, but gave significantly less inhibition of fibrinolysis in every experiment, particularly when the clot was compacted by platelet-mediated clot retraction or by squeezing. Thus, it was concluded that alpha(2)PI cross-linked to fibrin plays a significant role in inhibition of physiologically occurring fibrinolysis. It is further suggested that the absence of cross-linked alpha(2)PI contributes to accelerated fibrinolysis and hemorrhagic tendency in patients with congenital deficiency of fibrin-stabilizing factor.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7199538      PMCID: PMC371009          DOI: 10.1172/jci110479

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  26 in total

1.  Human Factor XIII from plasma and platelets. Molecular weights, subunit structures, proteolytic activation, and cross-linking of fibrinogen and fibrin.

Authors:  M L Schwartz; S V Pizzo; R L Hill; P A McKee
Journal:  J Biol Chem       Date:  1973-02-25       Impact factor: 5.157

2.  Characterization of human plasminogen. II. Separation and partial characterization of different molecular forms of human plasminogen.

Authors:  P Wallén; B Wiman
Journal:  Biochim Biophys Acta       Date:  1972-01-26

3.  [A quantitative determination of factor 13 with anti-factor 13 serum].

Authors:  H Bohn; H Haupt
Journal:  Thromb Diath Haemorrh       Date:  1968-07-31

4.  Solid state lactoperoxidase: a highly stable enzyme for simple, gentle iodination of proteins.

Authors:  G S David
Journal:  Biochem Biophys Res Commun       Date:  1972-07-25       Impact factor: 3.575

5.  A rapid method for the purification of bovine thrombin and the inhibition of the purified enzyme wtih phenylmethylsulfonyl fluoride.

Authors:  R L Lundblad
Journal:  Biochemistry       Date:  1971-06-22       Impact factor: 3.162

6.  The reliability of molecular weight determinations by dodecyl sulfate-polyacrylamide gel electrophoresis.

Authors:  K Weber; M Osborn
Journal:  J Biol Chem       Date:  1969-08-25       Impact factor: 5.157

7.  Kinetic studies with transglutaminases. The human blood enzymes (activated coagulation factor 13 and the guinea pig hair follicle enzyme.

Authors:  S I Chung; J E Folk
Journal:  J Biol Chem       Date:  1972-05-10       Impact factor: 5.157

8.  Cross-linking of cold-insoluble globulin by fibrin-stabilizing factor.

Authors:  D F Mosher
Journal:  J Biol Chem       Date:  1975-08-25       Impact factor: 5.157

9.  Identification and some properties of a new fast-reacting plasmin inhibitor in human plasma.

Authors:  D Collen
Journal:  Eur J Biochem       Date:  1976-10-01

10.  Isolation and characterization of alpha2-plasmin inhibitor from human plasma. A novel proteinase inhibitor which inhibits activator-induced clot lysis.

Authors:  M Moroi; N Aoki
Journal:  J Biol Chem       Date:  1976-10-10       Impact factor: 5.157

View more
  42 in total

1.  The impact of factor XIIIa V34L polymorphism on plasma factor XIII activity in the Chinese and Asian Indians from Singapore.

Authors:  Chew-Kiat Heng; Suman Lal; Nilmani Saha; Poh-Sim Low; M Ilyas Kamboh
Journal:  Hum Genet       Date:  2003-10-31       Impact factor: 4.132

2.  Factor XIII cotreatment with hemostatic agents in hemophilia A increases fibrin α-chain crosslinking.

Authors:  J D Beckman; L A Holle; A S Wolberg
Journal:  J Thromb Haemost       Date:  2017-11-20       Impact factor: 5.824

Review 3.  Haemostatic system in inflammatory bowel diseases: new players in gut inflammation.

Authors:  Franco Scaldaferri; Stefano Lancellotti; Marco Pizzoferrato; Raimondo De Cristofaro
Journal:  World J Gastroenterol       Date:  2011-02-07       Impact factor: 5.742

Review 4.  Factor XIII is a key molecule at the intersection of coagulation and fibrinolysis as well as inflammation and infection control.

Authors:  Akitada Ichinose
Journal:  Int J Hematol       Date:  2012-04-05       Impact factor: 2.490

5.  Coagulation factor XIIIa substrates in human plasma: identification and incorporation into the clot.

Authors:  Camilla Lund Nikolajsen; Thomas F Dyrlund; Ebbe Toftgaard Poulsen; Jan J Enghild; Carsten Scavenius
Journal:  J Biol Chem       Date:  2014-01-17       Impact factor: 5.157

6.  Fibrin glue inhibits migration of ocular surface epithelial cells.

Authors:  A M Yeung; L A Faraj; O D McIntosh; V K Dhillon; H S Dua
Journal:  Eye (Lond)       Date:  2016-07-01       Impact factor: 3.775

7.  Evidence that alpha2-antiplasmin becomes covalently ligated to plasma fibrinogen in the circulation: a new role for plasma factor XIII in fibrinolysis regulation.

Authors:  M W Mosesson; K R Siebenlist; I Hernandez; K N Lee; V J Christiansen; P A McKee
Journal:  J Thromb Haemost       Date:  2008-06-16       Impact factor: 5.824

8.  Aspirin inhibits vascular plasminogen activator activity in vivo. Studies utilizing a new assay to quantify plasminogen activator activity.

Authors:  R I Levin; P C Harpel; D Weil; T S Chang; D B Rifkin
Journal:  J Clin Invest       Date:  1984-08       Impact factor: 14.808

9.  Atherothrombosis and Thromboembolism: Position Paper from the Second Maastricht Consensus Conference on Thrombosis.

Authors:  H M H Spronk; T Padro; J E Siland; J H Prochaska; J Winters; A C van der Wal; J J Posthuma; G Lowe; E d'Alessandro; P Wenzel; D M Coenen; P H Reitsma; W Ruf; R H van Gorp; R R Koenen; T Vajen; N A Alshaikh; A S Wolberg; F L Macrae; N Asquith; J Heemskerk; A Heinzmann; M Moorlag; N Mackman; P van der Meijden; J C M Meijers; M Heestermans; T Renné; S Dólleman; W Chayouâ; R A S Ariëns; C C Baaten; M Nagy; A Kuliopulos; J J Posma; P Harrison; M J Vries; H J G M Crijns; E A M P Dudink; H R Buller; Y M C Henskens; A Själander; S Zwaveling; O Erküner; J W Eikelboom; A Gulpen; F E C M Peeters; J Douxfils; R H Olie; T Baglin; A Leader; U Schotten; B Scaf; H M M van Beusekom; L O Mosnier; L van der Vorm; P Declerck; M Visser; D W J Dippel; V J Strijbis; K Pertiwi; A J Ten Cate-Hoek; H Ten Cate
Journal:  Thromb Haemost       Date:  2018-01-29       Impact factor: 5.249

10.  Exogenous fibrin matrix precursors stimulate the temporal progress of nerve regeneration within a silicone chamber.

Authors:  L R Williams
Journal:  Neurochem Res       Date:  1987-10       Impact factor: 3.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.